Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Ketotifen Eye Drops for Treating Seasonal Allergic Conjunctivitis in Patients

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the treatment of Seasonal Allergic Conjunctivitis, a common eye condition that occurs during certain times of the year and causes symptoms like itchy, red, and watery eyes. The study will evaluate the effectiveness and safety of an eye drop solution containing Ketotifen, a medication known to help relieve allergy symptoms. Two different formulations of Ketotifen eye drops are being tested: one is called Ketoftil, and the other is referred to by its code name KET-001. Additionally, a placebo will be used for comparison purposes.

The purpose of the study is to determine how well these Ketotifen eye drops work in reducing the symptoms of Seasonal Allergic Conjunctivitis and to ensure they are safe for use. Participants in the study will be randomly assigned to receive either the Ketotifen eye drops, Ketoftil, or a placebo. The study will last for a period of two weeks, during which participants will use the eye drops and report any changes in their symptoms. The study is designed to be double-blind, meaning neither the participants nor the researchers will know which treatment each participant is receiving, to ensure unbiased results.

Throughout the study, participants will be asked to self-assess their level of eye itching using a simple scale. Other symptoms, such as eye redness, tearing, and eyelid swelling, will be evaluated by the study investigators at various intervals. The overall safety and tolerability of the treatments will also be monitored. This trial aims to provide valuable information on the potential benefits of Ketotifen eye drops for individuals suffering from Seasonal Allergic Conjunctivitis.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be randomly assigned to receive either the active medication, ketotifen ophthalmic solution 0.5 mg/ml, or a placebo. The placebo contains ingredients like glycerol, hydrochloric acid, and water for injections, but does not have the active medication.

    The study is double-blind, meaning neither you nor the researchers will know which treatment you are receiving to ensure unbiased results.

  2. Step 2

    Medication administration

    You will be instructed to use the eye drops as directed. The dosage is 0.5 mg/ml of ketotifen, administered through eye drops.

    The frequency and duration of administration will be explained to you by the study team. Ensure to follow the instructions carefully for the entire duration of the study.

  3. Step 3

    Self-assessment of symptoms

    You will be asked to self-assess your ocular itching using a 5-point scale. This will occur between the first visit (baseline) and the fifth visit, which is 14 days later.

    Your feedback is crucial for evaluating the effectiveness of the treatment.

  4. Step 4

    Investigator assessments

    The study team will assess your conjunctival redness at 30 minutes, 2 days, 7 days, and 14 days after the first administration of the eye drops. This will be done using a specific scale known as the Efron scale.

    Other symptoms such as tearing, eyelid swelling, and conjunctival chemosis will also be evaluated at the same intervals using different scales.

  5. Step 5

    Product tolerability assessment

    The tolerability of the product will be assessed at 30 minutes, 2 days, 7 days, and 14 days after the first administration. This will be done using a tool called the Visual Analog Scale (VAS).

    Your comfort and any side effects experienced will be recorded to ensure the safety of the treatment.

  6. Step 6

    Safety evaluation

    Throughout the study, any adverse events or side effects you experience will be documented. This is to ensure the safety of the treatment and to monitor any potential risks.

    Both quantitative (numerical) and qualitative (descriptive) evaluations will be conducted to assess safety.

Who can join the trial?

4 criteria

  • Adult patient (age from 18 to 65 years old).
  • Diagnosis of Seasonal Allergic Conjunctivitis (SAC) confirmed through a skin test and/or a validated IgE radioallergosorbent test (RAST) to the relevant seasonal allergy for the geographic area within the past 12 months. IgE RAST is a blood test that helps identify specific allergies.
  • Experiencing symptoms or exceeding an appropriate minimum level of symptoms at the time of enrollment. Patients must have at least one of the following symptoms: redness, tearing, itchy eyes, eyelid swelling, or conjunctival chemosis with a grade score of one. Conjunctival chemosis is swelling of the tissue lining the inside of the eyelids and the white part of the eye.
  • Patient has given written informed consent approved by the Ethics Committee (EC). This means the patient agrees to participate in the study after being informed about it.

Who cannot join the trial?

3 criteria

  • Patients who are not diagnosed with seasonal allergic conjunctivitis cannot participate. This is an eye condition caused by allergies, leading to red, itchy, and watery eyes.
  • Patients who are younger than 4 years old or older than 3 years old cannot participate. This means the study is for children aged 4 to 3 years old.
  • Patients who are part of a vulnerable population cannot participate. A vulnerable population includes groups who may need special protection, like pregnant women or people with certain disabilities.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Ketotifen Ophthalmic Solution is an eye drop used to relieve symptoms of seasonal allergic conjunctivitis, which is an eye condition caused by allergies. This medication works by blocking certain natural substances in the body that cause allergic symptoms, such as itching and redness in the eyes. It helps to make your eyes feel more comfortable during allergy season.

What is already known about the treatment

Ketotifen Ophthalmic Solution – This medication is administered as eye drops and is used to treat seasonal allergic conjunctivitis, which is an eye inflammation caused by allergies. Ketotifen works by blocking certain natural substances called histamines that are responsible for allergic symptoms. It is classified as an antihistamine and is currently being studied in clinical trials to evaluate its effectiveness and safety compared to other treatments.

Investigated diseases

Seasonal Allergic Conjunctivitis – Seasonal Allergic Conjunctivitis is an inflammation of the conjunctiva, the membrane covering the white part of the eyes and the inner side of the eyelids, caused by allergens such as pollen. It typically occurs during specific seasons when pollen levels are high. The condition is characterized by symptoms such as itching, redness, tearing, and swelling of the eyes. These symptoms result from the body's immune response to allergens, leading to the release of histamines and other chemicals. The condition can cause discomfort and may interfere with daily activities, but it does not usually affect vision. Symptoms often improve when the exposure to allergens is reduced or eliminated.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-503185-23-00Protocol codeKET-001Estimated enrolment253 patientsSponsorGenetic S.p.A.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.